LACE+ and MRS Score Readmission Rate Assessment

Hospitalism Clinical Trial

Official title:

Comparing the Predictive Strength of the LACE+ Index With the MedWise Rise Score on Hospital Readmission Rates: a Non-inferiority Observational Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04365673
• Other study ID #: TRHC_RD_LACEMRS_2020
• Status: Terminated
• Start date: July 7, 2020
• Est. completion date: March 1, 2021

Study information

• Verified date: March 2022
• Source: Tabula Rasa HealthCare
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A study to demonstrate that the LACE+ score in non-inferior to the medication risk score when predicting 30-day readmission post hospital discharge.

Description:

The objective of this study is evaluate a program that provides transition of care services to a local Tucson hospital involving activities designed to reduce 30 day post hospital discharge readmission rates. The organization has had a fee for service contract with this hospital since 2017 to provide pharmacist delivered transition of care services. The organization collects internal tracking outcome data as part of the contract deliverable and is required to report it to the hospital once per month. The investigators look to assess LACE+ and medication risk scores to learn if there is an association with the 30 day post hospital discharge readmission rate post pharmacist intervention. The outcomes will not be generalizable and will be reported back to the hospital client to demonstrate value added.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 100
• Est. completion date: March 1, 2021
• Est. primary completion date: March 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 88 Years

Eligibility

Inclusion Criteria:

• Those referred to receive transition of care services between January 2018 to December 2019 and were discharged on 10 or more medications.

Exclusion Criteria:

• 89 years or older

Related Conditions & MeSH terms

• Hospitalism

Intervention

Other:
• Pharmacist transition of care consultation
Pharmacist-delivered comprehensive medication review

Locations

Country	Name	City	State
United States	Tabula Rasa HealthCare	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Tabula Rasa HealthCare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Readmission	Readmission within 30-days post hospital discharge	2018 - 2019